PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas.

Abstract Recent studies have shown that lymphoid enhancer binding factor 1 (LEF1) is a useful marker for chronic lymphocytic B-cell leukemia (CLL)/small lymphocytic lymphoma. Yet, it is not still being widely used in a diagnostic setting. In this study, we document the experience with LEF1 immunohistochemistry during routine diagnostics.
PMID
Related Publications

Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.

Expression of LEF1 in mantle cell lymphoma.

Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.

LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma.

Flow cytometric analysis of lymphoid enhancer-binding factor 1 in diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors

Mayor MeshTerms
Keywords

CLL

Immunohistochemistry

LEF1

Routine diagnostics

Journal Title american journal of clinical pathology
Publication Year Start




PMID- 28395058
OWN - NLM
STAT- MEDLINE
DA  - 20170410
DCOM- 20170414
LR  - 20170414
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 147
IP  - 3
DP  - 2017 Mar 01
TI  - Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in 
      Small B-Cell Lymphomas.
PG  - 292-300
LID - 10.1093/ajcp/aqw208 [doi]
AB  - Objectives: Recent studies have shown that lymphoid enhancer binding factor 1
      (LEF1) is a useful marker for chronic lymphocytic B-cell leukemia (CLL)/small
      lymphocytic lymphoma. Yet, it is not still being widely used in a diagnostic
      setting. In this study, we document the experience with LEF1 immunohistochemistry
      during routine diagnostics. Methods: In total, 191 B-cell lymphoma cases from
      Hammersmith Hospital, Imperial College NHS Healthcare Trust (London, UK) were
      investigated by immunohistochemistry for LEF1 during routine diagnostic workup.
      These cases included both bone marrow trephines and lymph node biopsy specimens. 
      The monoclonal antibody clone EPR2029Y was used. Results: LEF1 expression was
      strong and diffuse (>70% of cells) in most cases. Few CLL cases showed a staining
      in proliferation centers only. Seventy-seven of 80 CLL cases expressed LEF1.
      Other entities expressing LEF1 included one of 38 follicular lymphomas, two of 33
      marginal zone lymphomas, and one diffuse large B-cell lymphoma with a background 
      of follicular lymphoma grade 3B. Sensitivity for LEF1 for the diagnosis of CLL
      was 0.96, and specificity was 0.93. Conclusions: In this study, we could
      demonstrate the diagnostic utility of LEF1. LEF1 is a sensitive and specific
      marker for CLL and is helpful in the diagnosis of diagnostically challenging
      small B-cell lymphomas.
FAU - Menter, Thomas
AU  - Menter T
AD  - From the Department of Cellular and Molecular Pathology, Hammersmith Hospital
      Campus, Imperial College Healthcare NHS Trust, London, UK; and.
AD  - Institute of Pathology, University Hospital Basel, Basel, Switzerland.
FAU - Trivedi, Pritesh
AU  - Trivedi P
AD  - From the Department of Cellular and Molecular Pathology, Hammersmith Hospital
      Campus, Imperial College Healthcare NHS Trust, London, UK; and.
FAU - Ahmad, Raida
AU  - Ahmad R
AD  - From the Department of Cellular and Molecular Pathology, Hammersmith Hospital
      Campus, Imperial College Healthcare NHS Trust, London, UK; and.
FAU - Flora, Rashpal
AU  - Flora R
AD  - From the Department of Cellular and Molecular Pathology, Hammersmith Hospital
      Campus, Imperial College Healthcare NHS Trust, London, UK; and.
FAU - Dirnhofer, Stephan
AU  - Dirnhofer S
AD  - Institute of Pathology, University Hospital Basel, Basel, Switzerland.
FAU - Tzankov, Alexandar
AU  - Tzankov A
AD  - Institute of Pathology, University Hospital Basel, Basel, Switzerland.
FAU - Naresh, Kikkeri N
AU  - Naresh KN
AD  - From the Department of Cellular and Molecular Pathology, Hammersmith Hospital
      Campus, Imperial College Healthcare NHS Trust, London, UK; and.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (LEF1 protein, human)
RN  - 0 (Lymphoid Enhancer-Binding Factor 1)
SB  - AIM
SB  - IM
MH  - Biomarkers, Tumor/*analysis
MH  - Humans
MH  - Immunohistochemistry
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis
MH  - Lymphoid Enhancer-Binding Factor 1/analysis/*biosynthesis
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - CLL
OT  - Immunohistochemistry
OT  - LEF1
OT  - Routine diagnostics
EDAT- 2017/04/11 06:00
MHDA- 2017/04/15 06:00
CRDT- 2017/04/11 06:00
AID - 3063263 [pii]
AID - 10.1093/ajcp/aqw208 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2017 Mar 1;147(3):292-300. doi: 10.1093/ajcp/aqw208.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>